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Abstract: Selenium and selenocompounds have attracted the attention and the efforts of scientists
worldwide due to their promising potential applications in cancer prevention and/or treatment.
Different organic selenocompounds, with diverse functional groups that contain selenium, have been
reported to exhibit anticancer and/or chemopreventive activity. Among them, selenocyanates,
selenoureas, selenoesters, selenium-containing heterocycles, selenium nanoparticles, selenides and
diselenides have been considered in the search for efficiency in prevention and treatment of cancer
and other related diseases. In this review, we focus our attention on the potential applications
of selenides and diselenides in cancer prevention and treatment that have been reported so far.
The around 80 selenides and diselenides selected herein as representative compounds include
promising antioxidant, prooxidant, redox-modulating, chemopreventive, anticancer, cytotoxic and
radioprotective compounds, among other activities. The aim of this work is to highlight the
possibilities that these novel organic selenocompounds can offer in an effort to contribute to inspire
medicinal chemists in their search of new promising derivatives.
Keywords: selenium; selenocompounds; selenides; diselenides; antioxidants; chemoprevention;
anticancer compounds; cytotoxicity; cytostaticity
1. Introduction
Various authors have extensively reviewed the different applications of selenium in human
health [1–4]. Selenium is an essential element that forms part of the selenoaminoacids selenomethionine
(1, Figure 1a) and selenocysteine (2). The latest is an essential constituent of the selenoproteins [5–7] and
its deficiency can cause serious disorders [1,2]. Selenoproteins have crucial functions for human health.
The most known are the gluthathione peroxidases, the iodothyronine deiodinases, the thioredoxin
reductases and the selenoprotein P. The different glutathione peroxidases (GPx) are involved in the
elimination of free radicals; the iodothyronine deiodinases enable the activation and deactivation of
thyroid hormones. Thioredoxin reductases regenerate the thioredoxin (an important antioxidant class
of proteins), and the selenoprotein P is involved in the transport of selenium in plasma and in the
antioxidant defense against free radicals in lipids [5–7].
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An intense research in the chemopreventive and/or anticancer activity of organic and inorganic 
selenium-containing compounds has been developed, as has been reviewed by different authors [8–
14]. The duality of selenium as an antioxidant and as a prooxidant agent provides the basis for its 
potential applications in both cancer prevention and treatment. This dual chemopreventive and 
anticancer action has been extensively discussed or reported by different authors [15–18]. Regarding 
the chemopreventive activity, a mechanism usually exerted by different selenocompounds is the 
glutathione peroxidase-like activity [19]. Although inorganic selenocompounds may be superior 
chemopreventive agents than organic ones, current research is focused on the latter group due to 
their lower toxicity risk [20]. Among the inorganic selenocompounds, selenite can be highlighted by 
its chemopreventive [21] and anticancer action [22]. 
On the other hand, the mechanisms of action of the organic selenocompounds are very diverse 
[23]. Some of the most frequent are the reduction of oxidative stress through the elimination of free 
radicals [24,25], i.e., the induction of mutations [26], the cytotoxic activity [27] and the triggering of 
apoptotic events [28,29]. Nevertheless, certain selenocompounds can act through other less usual 
mechanisms, such as the inhibition of angiogenesis [30], the inhibition of the efflux pumps in cancer 
multidrug resistant cell lines [31] and the enhancement of the activity of chemotherapeutic drugs [32]. 
The chemical structure of anticancer and chemopreventive organic selenocompounds also shows a 
great variety, including selenocyanates [33], selenoureas [34], selenoesters [35], heterocycles with 
endocyclic selenium [36], selenium nanoparticles [37], selenides and diselenides.  
Herein, we review an anticancer and a chemopreventive activity of both selenides and 
diselenides, with a special attention to mechanisms of their biological action. The question of 
diselenides symmetry, as a feature favorable for anticancer activity [38], is also under consideration. 
2. Selenides and Diselenides with Therapeutic Perspective 
2.1. Naturally Occurring Selenides and Diselenides 
Diselenides have received significant attention, not only because this moiety is usually found 
among the metabolites of the dietary compounds but also particularly because they have been 
postulated as one of the most important species in redox-cycling. In line with this, selenocystine, a 
naturally occurring diselenide (3, Figure 1b), exhibits strong antioxidant properties [39] and has been 
considered in several studies related to chemoprevention. Thus, it was effective against 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induced lung tumors in a specific mouse 
model sensitive to chemical carcinogenesis (the A/J mouse model) when administered in a pre-
initiation period to tumor development, or, alternatively, when supplementation was restricted to a 
post-initiation period [40].  
In a different study, 3 was found to trigger apoptosis in human breast adenocarcinoma MCF-7 
cells through kinase regulation [41]. Induction of apoptosis was also attributed to 3 in HepG2 human 
hepatoma cells and in isolated rat liver mitochondria [42]. In this case, the proposed mechanism of 
apoptosis involved the opening of the mitochondrial permeability transition pores (and the 
associated loss of Δψm, mitochondrial swelling and cytochrome c release), which is mediated by the 
cross-linking of protein thiol groups and by the generation of superoxide radical anions (O2•−) 
through reaction with glutathione (GSH) [42]. Selenocystamine (4) also oxidized the protein thiol 
groups in isolated mitochondria and in crude extracts of HepG2 cells, but not in intact HepG2 cells. 
These lines of evidence suggest that the action was similar to that exerted by 3, precluding its inability 
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An intense research in the chemopreventive and/or anticancer activity of organic and inorganic
selenium-containing compounds has been developed, as has been reviewed by different authors [8–14].
The duality of selenium as an antioxidant and as a prooxidant agent provides the basis for its potential
applications in both cancer prevention and treatment. This dual chemopreventive and anticancer action
has been extensively discussed or reported by different authors [15–18]. Regarding the chemopreventive
activity, a mechanism u ually exerted by different selenocompounds is the gl tathione peroxidase-like
activity [19]. Al hough inorg ic selenocompounds may be superior chemoprev ntive agents han
organic ones, current re earch is focused on the l tter group due to their lower toxicity r sk [20]. Among
the inorganic s lenocompoun s, selenite c n be highlighted by its chemopreventive [21] and anticancer
action [22].
On the other hand, the mechanisms of action of the organic selenocompounds are very diverse [23].
Some of the most frequent are the reduction of oxidative stress through the elimination of free
radicals [24,25], i.e., the induction of mutations [26], the cytotoxic activity [27] and the triggering of
apoptotic events [28,29]. Nevertheless, certain selenocompounds can act through other less usual
mechanisms, such as the inhibition of angiogenesis [30], the inhibition of the efflux pumps in cancer
multidrug resistant cell lines [31] and the enhancement of the activity of chemotherapeutic drugs [32].
The chemical structure of anticancer and chemopreventive organic selenocompounds also shows
a great variety, including selenocyanates [33], selenoureas [34], selenoesters [35], heterocycles with
endocyclic selenium [36], selenium nanoparticles [37], selenides and diselenides.
Herein, we review an anticancer and a chemopreventive activity of both selenides and diselenides,
with a special attention to mechanisms of their biological action. The question of diselenides symmetry,
as a feature favorable for anticancer activity [38], is also under consideration.
2. Selenides and Diselenides with Therapeutic Perspective
2.1. Naturally Occurring Selenides and Diselenides
Diselenides have received significant attention, n t only because this moiety is usually found
among the metabolites of the dietary compounds but also particularly because they ave been
postulated as o e of the most impor ant speci s in dox-cycling. In line with th s, selenocystine,
a naturally occurring diselenide (3, Figure 1b), exhibits strong antioxidant properti s [39] and has
been considered in several studies related to chemoprevention. T us, it was effective against
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induced lung tumors in a specific mouse
model sensitive to chemical carcinogenesis (the A/J mouse model) when administered in a
pre-initiation period to tumor development, or, alternatively, when supplementation was restricted to
a post-initiation period [40].
In a different study, 3 was found to trigger apoptosis in human breast adenocarcinoma MCF-7
cells through kinase regulation [41]. Induction of apoptosis was also attributed to 3 in HepG2 human
hepatoma cells and in isolated rat liver mitochondria [42]. In this case, the proposed mechanism of
apoptosis involved the opening of the mitochondrial permeability transition pores (and the associated
loss of ∆ψm, mitochondrial swelling and cytochrome c release), which is mediated by the cross-linking
of protein thiol groups and by the generation of superoxide radical anions (O2•−) through reaction
with glutathione (GSH) [42]. Selenocystamine (4) also oxidized the protein thiol groups in isolated
mitochondria and in crude extracts of HepG2 cells, but not in intact HepG2 cells. These lines of
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evidence suggest that the action was similar to that exerted by 3, precluding its inability to cross the
cell membrane. Additionally, dimethyldiselenide (5), another naturally occurring diselenide, has been
reported to be active against oxidative damage [43].
2.2. Synthetic Diselenides
In addition to biologically existing diselenides, a variety of synthetic diselenides has exhibited
protective potential. Due to the high number of diselenides, they are reviewed herein in function
of their biological activity: antioxidant activity, prooxidant/redox-modulating, kinase-modulating,
antiproliferative/cytotoxic and apoptotic. The chemical names of mentioned diselenides are
summarized in Table 1.
Table 1. Synthetic diselenides mentioned.
Compound Compound
6 diphenyl diselenide 26 bis[2-(estra-1,3,5(10)-trien-17-one-3-yl)oxyethyl]diselenide
7 dibenzyl diselenide 27 bis[(25R)-16β-acetoxy-3β-hydroxy-22-oxocholest-5-en-26-yl]diselenide
9 diethyl diselenide, 28a naphtho[1,8-cd][1,2]diselenole
10 bis(4-clorophenyl) diselenide 28b 3,8-dimethoxynaphtho[1,8-cd][1,2]diselenole
11 3′3-ditrifluoromethyldiphenyl diselenide 29 dipropyl diselenide
12 p-methoxybenzeneselenol 30 dibutyl diselenide
13 3,3′-diselenodipropionic acid 31 diquinolyl-8-yl diselenide
14 binaphthyl diselenide 32 4,4′-diamino-3′,3-dicarboxydiphenyl diselenide
15 dipyrid-2-yl diselenide 36 6,6′-diselanediylbis(N-phenylhexanamide)
16 2′2-diaminodiphenyl diselenide 37a 6,6′-dichlorodipyridazyn-2-yl diselenide
17 8-(2-(8-(dimethylamino)naphthalen-1-yl)diselanyl)-N,N-dimethylnaphthalen-1-amine 37b 6,6
′-di(propoxy)dipyridazyn-2-yl diselenide
18 (2-(2-(2-((dimethylamino)methyl)phenyl)diselanyl)phenyl)-N,N-dimethylmethanamine 37c 6,6
′-di(isopentyloxy)dipyridazyn-2-yl diselenide
19
2-(2-(2-((dimethylamino)methyl)-6-methoxyphenyl)
diselanyl)-3-methoxyphenyl)-N,N-
dimethylmethanamine
37d 6,6′-di(propylthio)dipyridazyn-2-yl diselenide
20
(1-(2-(2-((dimethylamino)methyl)naphthalen-1-yl)
diselanyl)naphthalen-2-yl)-N,N-
dimethylmethanamine
38 2-chloro-6-(2-(6-chloropyridin-2-yl)diselanyl)pyridine
21 1,2-bis(2,4-dinitrophenyl)diselane 39 2,2′- di(phenylethyl) diselenide
22 bis(2-(1(R,S)-(N,N-dimethylamino)ethyl)ferrocen-1-yl)diselenide 40 dibenzhydryl diselenide
23 bis(2-(N-phenylcarbamoyl)ferrocen-1-yl) diselenide 41 1,2-bis(isoindoline-1,3-dione-2 ethyl)diselane
24a 5-(4-methoxyphenyl)-4-(2-(5-(4-methoxyphenyl)-1-methyl-1H-imidazol-4-yl)diselanyl)-1-methyl-1H-imidazole 42 1,2-bis(2-morpholinoethyl)diselane
24b 5-(4-chlorophenyl)-4-(2-(5-(4-chlorophenyl)-1-methyl-1H-imidazol-4-yl)diselanyl)-1-methyl-1H-imidazole 43 4
′,4-dimethoxydiphenyl diselenide
25a bis-4-[1-[(4’-methoxy)phenyl]-4-seleno-imidazole] 44 3′,5′,3,5-tetratrifluoromethyl-diphenyl diselenide
25b 4,4′-diselanediylbis(N-benzylbenzamide) 45 4′,4-diaminodiphenyl diselenide
25c N-(1,1-dioxidobenzo[b]thiophen-2-yl)-4-((4-((1,1-dioxidobenzo[b]thiophen-2-yl)carbamoyl)phenyl) diselaneyl)benzamide
2.2.1. Antioxidant Activities of Synthetic Diselenides: GPx-Like, Metal-Binding, Chemopreventive and
Free Radical Scavenging Potential
Diphenyl diselenide (6, Figure 2) has been evaluated in several studies and it is considered
a reference compound in the evaluation of the antioxidant properties and of the glutathione
peroxidase-like (GPx-like) activity [44–48]. Especially, 6 displayed a higher antioxidant activity than
both dibenzyl diselenide (7) and a group of asymmetric selenides represented by 8 [44]. Concerning
the protective role of diselenides on lipid peroxidation, 6 behaved as the most antioxidant compound
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among the different diaryl and dialkyl diselenides tested, regardless of the species (mice and rats) [46].
Dialkyl selenides, e.g., diethyl (9) and substituted diaryl diselenides such as di(p-clorophenyl)
diselenide (10), were effective against lipid peroxidation but showed differential antioxidant potential
in mice and rats, being more potent in mice [46].
The ability of diphenyl diselenide (6) to protect murine J774 macrophage-like cells from reactive
oxygen species (ROS) generated by the oxidation of low density lipoproteins (LDL) was proved by
Straliotto et al. [49]. The redox signaling effects of 6 were accompanied by the down-regulation of the
nuclear factor-κB (NF-κB), a transcription factor involved in pro-apoptotic pathways activated by ROS.
Melo et al. found that 6 was also able to protect breast (MCF-7) cancer cells from oxidative damage
induced by tamoxifen hormone therapy without interfering with its cytotoxicity [50]. They concluded
that, if used at low concentrations, 6 could be employed as a potent antigenotoxic agent to prevent the
risk of cancer induction.
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The meta-CF3 substituted diphenyl diselenide (11) has been reported as an anti-mutagenic and
anti-genotoxic selenium derivative [51]. It protected Chinese hamster lung fibroblasts (V79 cells)
against H2O2-induced DNA damage at doses as low as 12.5 µM. In addition, 11 mimics catalase
activity better than 6, both compounds giving rise to different products upon reaction with H2O2.
The dimethyl- (5), diphenyl- (6) and dibenzyl diselenides (7) induced quinone reductase
and glutathione-S-transferase activity [52]. The generated selenol derivatives (i.e., selenolates at
physiological pH) can be considered as the metabolites responsible for such responses.
Selenolates can be easily generated from selenols due to the high acidity of the Se-H bond
(which is more labile than the equivalent S-H and O-H bonds because of the higher polarizability of
selenium), that enables the rapid and almost complete ionization at physiological pH [53]. One of the
first selenols assayed for inhibition of carcinogenesis has been p-methoxyphenylselenol (12), which
showed effectiveness in the inhibition of azoxymethane-induced liver [54], colon and kidney [55]
tumors in rats.
On the other hand, the antioxidant and GPx activity of 3,3′-diselenodipropionic acid (13) has
been evaluated by Kunwar et al. [56]. The treatment with 13 prevented the depletion of the levels of
endogenous antioxidants (GSH) in red blood cells through free-radical-induced stress. However, in
comparison to sodium selenite or ebselen, its GPx activity was lower. Compound 13 has been also
evaluated as a radio-protective agent against whole-body γ-radiation on Swiss albino mice [57]. In this
in vivo study, authors concluded that 13 can attenuate radiation-induced DNA damage. Furthermore,
it can inhibit radiation-induced apoptosis in the spleen and can reverse radiation-induced alterations
in the expression of the pro-apoptotic BAX and the anti-apoptotic Bcl-2 genes.
Adding a second phenyl group to diphenyl selenide, converting it in binaphthyl diselenide (14),
revealed that it showed a significant antioxidant activity [58]. Compound 14 could exert a protective
action against 2-nitropropane (2-NP)-induced hepatoxicity in rats.
Including nitrogen into the phenyl ring, converting it in a pyridine ring (15), has provided
cytoprotective effects [59]. The 2-pyridyl derivative 15 caused the largest shift in the Cu+2 reduction
potential and was also the most promising in the metallothionein (MT) assay for the measurement of
catalytic activity. Similarly, the N-exocyclic aniline derivative 16 exhibited a noteworthy activity in the
antioxidant assays considered. Indeed, 16 behaved as a better antioxidant than ebselen in human skin
fibroblast (FCP7) cell culture under UVA-induced stress, thus suggesting that 16 could depict a leading
compound for the development of more effective [46] multi-functional antioxidants. According to
the authors, these different activities (GPx-like and metal binding characteristics of their nitrogen and
chalcogen groups) could explain the extraordinary protection exerted by these compounds against
the damage caused by ROS. The role of selenium-metal coordination in DNA damage inhibition was
reported to be essential in a parallel study [60].
The naphthylamine derivative 17 did not show GPx-like activity when this activity was evaluated
for selected intramolecularly-coordinated diorganyl diselenides [45]. In contrast, compounds with
phenyl or naphthyl rings substituted with a (dimethylamino)methyl group (18–20) were active and
these observations were attributed to the presence of better electron-donating groups in close proximity
to selenium [61]. Likewise, a good activity was found for 21, with an electron-withdrawing group
(a nitro group) in ortho position to selenium. The same authors had previously evaluated the thiol
peroxidase-like activity of related diselenides based on ferrocene, such as 22 [62]. The introduction of
the ferrocene moiety increased the activity, although the most important effect was suspected to be
exerted through the efficacy of the intramolecular N . . . Se coordination, as 23, with an amide group
and, thus, a less coordinating nitrogen atom, was only superior to 6 and 17 (GPx-like activity: 22 > 20 >
21 >> 18 > 23 >> 6 > 17).
Bhabak and Mugesh [63] reported the enhancement of the antioxidant activity of diselenides
compounds such as 18 by the introduction of a methoxy group as a substituent in ortho to selenium (19).
The observed increment of activity in compound 19 was investigated through kinetic and computational
methods and ascribed to the role of the methoxy group in altering the steric and electronic environment
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around selenium, in particular, preventing over-oxidation by peroxides and preventing thiol-exchange
reactions in the selenenylsulfide intermediate of the catalytic cycle. The same authors also found
an enhanced GPx activity of sec-amino-substituted diselenides analogous versus the analogous
tert-amine-based compounds [64].
The p-methoxyphenyl- (24a) and p-chlorophenyl-substituted (24b) compounds were the most
active molecules in a series of related imidazole-containing derivatives assayed for their GPx-like
activity and their capacity to be reduced by glutathione (GSH) [65]. Regarding GPx-like activity, they
were 4-fold more potent than ebselen, whilst they showed 3–5-fold more reactivity toward GSH than 6.
In general, the most effective compounds were those substituted at 5-position of the imidazole ring,
close to the selenium atom. Apart from this fact, no other clear structure–activity relationship emerged
from these antioxidant studies.
An interesting study by Romano et al. [66] compared the capability of new
selenocarbamate derivatives to scavenge the radical 1,1-diphenyl-2-picryl-hydrazyl (DPPH)
and 2,2-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), as well as their ability to mimic
GPx activity. Two families containing common active fragments, consisting of selenocyanate and
diselenide derivatives, did not differ much in their activities despite double amount of selenium (on a
molar basis) and symmetry in the case of diselenides. Among diselenides, 25a, 25b and 25c (Figure 2)
displayed potential radical scavenging activity for DPPH and ABTS, although they did not exhibit
GPx-like activity.
When evaluating the GPx-like activity of a group of selenosteroids (26 and 27, among others),
Fuentes-Aguilar et al. [67] found that the GPx-like activity was under that of ebselen for all the
compounds considered.
On some occasions, the chemoprotective activity of diselenides has been related to conformational
restriction. Thus, certain peri-diselenides (28a and 28b) have shown superior GPx-like activity than
acyclic diaryl diselenides [68]. It should be expected that several properties of the compounds worked
synergistically, however, as the introduction of methoxy groups in the naphthalene moiety made
chemoprevention increase for derivative 28b in comparison to 28a.
2.2.2. Prooxidant Activity and Redox Modulation Activity of Synthetic Diselenides
Dialkyl diselenides (29 and 30), in contrast to diaryl ones (6, 10, and 11), proved to behave as
prooxidants at low concentrations [46]. According to in vivo studies and despites its above-mentioned
antioxidant potential, 6 can also be toxic in certain conditions, depending on dose, species and route of
administration [69,70].
The intracellular redox modulation by selenocompounds has been deeply studied. Nevertheless,
the extracellular redox control has been only recently linked to the cellular uptake and to the cytotoxicity
of selected selenium-containing derivatives [71,72]. The extracellular redox status, in whose regulation
both cell surface and secreted redox-active proteins are involved, seems to be correlated with
several biological responses such as cell proliferation and apoptosis. The cysteine/cystine couple is
attributed to play a key-role in the extracellular redox state, whereas thioredoxin (Trx), thioredoxin
reductase (TrxR) and protein disulfide isomerase (PDI) are among the proteins whose expression
may increase the production of cysteine. Apart from phenylselenol (PhSeH) and ebselen, diphenyl
diselenide (6, Figure 2) and dibenzyl diselenide (7) have been pointed as inductors of extracellular
cysteine accumulation in murine macrophage RAW 264.7 cells and in differentiated human THP-1
monocytes [72]. Nevertheless, neither selenocystine (3, Figure 1) nor methylselenocysteine could
exert the same effects. The authors proposed a model where production of extracellular cysteine
increases because of the induction of TrxR1 expression on the cell surface by certain organoselenium
compounds. Again, selenolates are pointed as the putative bioactive species, as 6 and PhSeH showed
nearly identical cellular effects on a molar basis [72].
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Diethyl- (9) and dipropyl (29) diselenides demonstrated a higher potential for –SH group oxidation
than diaryl diselenides, presumably because the generated selenolates would be more nucleophilic.
Dibutyl diselenide (30) was prooxidant at low concentrations [46].
In contrast to endocyclic (15) and exocyclic (16) N-containing monocyclic diselenides,
the diquinolyl-8-yl diselenide (31) containing fused-ring systems acted as a prooxidant at 5 µM,
although it exerted a slightly protective action at 1 µM [59].
2.2.3. Kinase Modulation Activity of Synthetic Diselenides
In the frame of kinase modulation as a possible pathway in the mechanisms of action of
selenocompounds as anticancer agents [73], a library of organoselenium compounds was analyzed by
Plano et al. [74]. Compounds with a variety of aromatic, heteroaromatic and aliphatic nitrogen-containing
moieties (32–36, Figure 3) showed a noteworthy influence over different kinases. Among them,
the bis(4-amino-3-carboxyphenyl) diselenide derivative 32 showed a mild inhibition of cyclin kinase
(CDKs) activity. On the other hand, selenol-disubstituted pyrido[2,3-d]pyrimidine (33) and quinazoline
(34) derivatives were proposed as promising candidates against cancer and other diseases: they are
capable to produce a potent activation of the insulin-like growth factor 1 receptor (IGF-1R), playing thus
a major role in cancer growth, tumor cell survival and resistance to therapy [75]. In line with the former
compounds, the indol-containing diselenide 35 acted through inhibition of tyrosine kinase [73].
The antitumoral effect of the amide-containing derivative 36 [76] has been partially attributed to
its capability for inhibiting the PI3 kinase pathway (see Section 2.2.4).
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2.2.4. Antiproliferative and Cytotoxic Activity of Synthetic Diselenides
There are several Se-based compounds that can inhibit the growth of malignant cells.
The challen e of such comp unds is selectivity, in the s nse that the effect on normal cells should
ideally be m rginal. Among the compounds with ant prol ferative potent al, 5 (Figure 1), 6 and 7
(Figure 2), which have been already mentioned with regard to their antioxidant activity, inhibited cell
growth in murine hepatoma (Hepa 1c1c7) cells [52]. The authors pointed out that the inhibition of
cell growth correlated with their potential to induce quinone reductase and glutathione-S-transferase
activity. By contrast, the 3,3′-diselenodipropionic acid 13, described as a radio-protective agent and
a free-radical scavenger, was not found to be toxic toward lymphocytes and EL4 tumor cells at the
concentrations used [56].
Regarding the phenylcarbamate diselenides 25a, 25b a d 25c (Figure 2) [66], which showed radical
scavenging activity but l cked in GPx activity (menti ned above), they displayed the best in vitro
antiproliferative activities am ng several tested disel ni es agai st a panel of human tumor cell lines
including lung carcinoma (HTB-54), colon carcino a (HT-29), lymphocytic leukemia (CCRF-CEM),
breast adenocarcinoma (MCF-7) and prostate adenocarcinoma (PC-3). Unfortunately, most compounds
exhibited similar activities in both tumor and non-tumor cell lines. By a subsequent molecular
modeling analysis [77], it was concluded that the cytotoxic activity correlated with the greater or lesser
ability to release the active fragments: the central common fragment, the alcohol or phenols moieties,
or the corresponding selenol (RSeH) and selenenic acid (RSeOH) derivatives.
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For estrone and diosgenin-based diselenides (26 and 27), the in vitro antiproliferative activity
against a panel of six human solid tumor cell lines, when tested up to a 100 µM concentration, was
negligible [67]. Cancer cell lines included non-small cell lung (A549 and SW1573), breast (HBL-100
and T-47D), cervix (HeLa) and colon (WiDr) [67].
Substituted dipyridazinyl diselenides 37a–d (Figure 4), substituted diaralkyl diselenides
(7), substituted dipyridinyl diselenides 15 and 38, di(phenylethyl) diselenide (39), dibenzhydryl
diselenide (40), the phthalimide-containing diselenide 41 and the morpholine-containing diselenide 42
(Figures 2 and 4, respectively) have been recently evaluated on their antiproliferative ability against
human breast cancer MCF-7 cells [78]. The chloro-substituted pyridazine derivative 37a showed
the highest potency, markedly inhibiting MCF-7 cell growth with an IC50 value of 10.34 µM, in a
dose-dependent manner. In addition, other seven diselenides (37b, 37c, 37d, 38, 15, 41 and 42)
showed higher potency, in terms of IC50, than the positive control (5-fluorouracil) against MCF-7 cells,
suggesting the potential anticancer activity of these selenocompounds. The relatively broad diversity
of structures that gave rise to antiproliferative activities makes it difficult to deduce a structure–activity
relationship valid to explain the results, apart from the consideration of the symmetry that implies the
presence of the diselenide moiety in all of these compounds [78].
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Two of the active compounds in the abovementioned study of Kim et al. [78], phthalimide (41)
and morpholine (42) derivatives, depicted sp3 carbon atoms directly bonded to selenium. As indicated
above, most part of sy t etic sel nide-derivatives with reported anticancer activity depic Csp2-Se
bonds, ven though methylselenol has been proposed as the critical s lenium metabolite of the dietary
seleno-amino acids for anticancer activity [79]. Nevertheless, also compound 36 (Figure 3), described
by Gowda et al. [76], has alkylic C-Se bonds. A promising anticancer activity has been reported for this
symmetrical diarylalkyl diselenide. Compound 36 was tested in the prevention of early melanocytic
lesion development in laboratory-generated skin reconstructs of WM35 or WM115 melanoma cell
lines [76]. The topical application of 36 inhibited melanoma by up to 87% with negligible toxicological
effects. Mechanistically, its action corresponds to a histone deacetylase (HDAC) and PI3 kinase
pathway inhibitor. This combination o actions explains its efficacy in comparison to suberoylanilide
hydroxamic acid (SAHA), the best-known HDAC inhibitor at the time. Furthermore, results suggested
the efficacy of the indole derivative 35 (Figure 3) against other cancer types, as it was also able to
inhibit cell growth in pancreatic (MIA-PA-Ca-2), breast (MDA-MB-231), prostate (PC-3) or sarcoma
(HT-1080) cell lines.
2.2.5. Apoptotic Activity of Synthetic Diselenides
Diphenyl diselenide (6) can down-regulate the expression of the nuclear factor-κB (NF-κB),
which is a transcription factor involved in pro-apoptotic pathways activated by ROS [80].
Similarly, substituted iaryl diselenides 11 (Figure 2) and 43 (Figure 5) were shown to
induce a optosis in huma colon adeno arcinoma c lls (HT-29) [80]. Ne el et al. used the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay and flow cytometry
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analyses to show the effect of 11 and 43. They proposed that such action was produced through
activation of caspase-dependent and independent pathways, in addition to cell-cycle arrest mediated
by the p53, p21 and MYC genes.
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The cytotoxic and apoptotic potential of diselenide 44 (Figure 5) has been confirmed though
DNA cell cycle analysis and through microscopic monitoring of the formation of apoptotic bodies [81].
Among the 13 symmetric aromatic diselenides with a variety of substitution patterns evaluated
by Rizvi et al. [81], compound 44 showed the highest inhibition of cell growth in human leukemia
HL-60 cells (IC50 = 8 µM). Its cytotoxic potential against prostate (PC-3), breast (MCF-7), pancreatic
(MIA-PA-Ca-2) and colon (HCT-116) cancer cell lines was also demonstrated (IC50 values of 13, 18, 25
and 27 µM, respectively). The antiproliferative activity of 44 on HL-60 cells involved the inhibition
of the S phase of the cell cycle and the induction of apoptosis through the mitochondrial-dependent
pathway. The authors also determined the DNA binding ability of 44 using molecular docking, showing
that binding of the compound occurs selectively to the minor groove of DNA through hydrogen bonds
involving the fluorine atoms. This binding was reinforced through hydrophobic interactions mediated
by the benzene rings. Interestingly, pyridine-containing compound 15 (Figure 2) did not show any
remarkable pro-apoptotic potential against the series of cell lines mentioned above [81].
A comprehensive library including nine symmetrical diarylalkyl diselenides
(Ar-(CH2)n-Se-Se-(CH2)n-Ar; n = 0, 1) has been assayed for apoptotic potential in several cell
lines [82]. Breast adenocarcinoma (MCF-7) cells were considered, as well as human prostate (PC-3)
cells, lymphocytic leukemia (CCRF-CEM) cells and human colorectal adenocarcinoma (HT-29) cells.
Again, it was a diaryl diselenide (45, Figure 5) the compound which displayed the best therapeutic
profile regarding superoxide generation and cell cytotoxicity. Thus, aniline derivative (45) was the
most potent organoselenium compound (among 59 candidates) against human prostate (PC-3) cells
(IC50 = 1.7 µM) and was 8-fold more active than etoposide (IC50 = 13.6 µM), an agent commonly
used in the treatment of prostate cancer. Compound 45 also exhibited more cytotoxic potency
(IC50 = 4.3 µM) than etoposide (IC50 = 17.5 µM) in MCF-7 cells and showed noteworthy cytotoxic
effects both in CCRF-CEM cells (IC50 = 9.0 µM) and HT-29 cells (IC50 = 9.8 µM). Additionally,
compound 45 affected the cell cycle distribution of MCF-7 cells in the G2/M and S-phases. Moreover,
45 developed an apoptotic activity in CCRF-CEM cells, mediated by reactive oxygen species (ROS)
and similar to camptothecin, the pro-apoptotic compound used as positive control.
2.3. Synthetic Selenides
Organic selenides are less reported in the literature of anticancer reagents in comparison to
diselenide derivatives. Herein, the studies involving selenides are divided in two main activities:
antioxidant (redox modulating, antioxidant and chemopreventive compounds) and antitumoral
compounds (derivatives with antiproliferative, cytotoxic and apoptotic activity). The chemical names
of the mentioned selenides are summarized in Table 2.
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Table 2. Selenides mentioned in the text.
Compound
46 diallyl selenide
47 1,4-bis(3-(phenylselanyl)propyl)piperazine
48 trans-3,4-dihydroxyselenolane
50 a–e different substituted phenyl 3-hydroxypropyl selenides
51 3-(phenylselanyl)-1-methyl-1H-indole
52a,
52b
6-(4-methylphenyl)selanylpurine
6-(4-chlorophenyl)selanylpurine
53 2-methyl-3-(phenylselanyl) naphthalene-1,4-dione
54a 2,3-bis(phenylselanyl)naphthalene-1,4-dione
54b 5,8-dihydroxy-2,3-bis(phenyl-selanyl)naphthalene-1,4-dione
55 2,3-bis((2,2-diethoxyethyl)selanyl)naphthalene-1,4-dione
56a 5′-(phenylseleno)zidovudine
56b 5′-(4-methylphenylseleno)zidovudine
56c 5′-(4-chlorophenylseleno)zidovudine
57 3-bromo-4-(4-(((4-fluorophenyl)selanyl)methyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromene-5,6-dione
58 2-(2-acetoxybenzamido)-3-(methylselanyl)propanoic acid
59 selenide-containing indole chalcone derivatives
60 (3,4-dimethoxy-5-(methylselanyl)phenyl)(1H-indol-5-yl)methanone
61 (3,4-dimethoxy-5-(methylselanyl)phenyl)(1H-indol-4-yl)methanone
2.3.1. Redox-Modulating and Antioxidant and Chemo-Preventive Activities of Synthetic Selenides
The diallyl selenide 46 (Figure 5) exhibited significant anti-carcinogenic activity when assayed
in a murine (DMBA)-induced mammary tumor model in a study performed to compare the
chemopreventive potential of organoselenium compounds versus the corresponding sulfur analogs
against cancer [83]. Through administration in a pre-initiation period to tumor development,
the protective activity of this symmetric selenide resulted around 300 times superior to its sulfur
isoster (diallyl sulfide). In a more recent research work by Mecklenburg et al. [84], the piperazine
compound 47, which combines redox catalysis with metal binding properties, was virtually non-toxic
(at concentrations up to 50 µM) against human SK-Mel-5 melanoma cells in the absence of H2O2
(91% survival at 25 µM), whereas it showed a toxicity in the presence of H2O2 2–3-fold higher than
in its absence (65% survival at 25 µM). As compound 47 (Figure 5) was somehow able to recognize
the particular redox state of the cells and, according to this state, exert either an antioxidative or a
prooxidative action, it has been considered a sensor/effector agent.
Some additional selenides have been studied from the point of view of their antioxidant activity,
but on these occasions, they have not been explicitly connected to anticancer research. For instance,
Kumakura et al. [85] evaluated the GPx-like activity [86] of the water-soluble cyclic selenide 48
(Figure 5). In the same way as it occurred with cyclic diselenides 28 (Figure 2), the derivative 48
exerted higher antioxidant catalytic activity than its linear analogs 49. According to the authors,
conformational restriction increased the HOMO energy level and made the selenium atom more
exposed. Other selenides, such as 50a–c (Figure 5), provided fast reaction rates for the reduction of
H2O2 with thiols by both high-performance liquid chromatography (HPLC) and nuclear magnetic
resonance (NMR)-based assays [87]. The fact that rates were more elevated than for their unsubstituted
or otherwise methoxy-substituted analogues was attributed to resonance stabilization of increased
positive charge on the selenium atom during the rate determining oxidation step. The polyethylene
glycol (PEG) derivatives 50d and 50e were prepared to increase aqueous solubility and they also
afforded remarkable activity. Noteworthy, both the non-PEGylated and PEGylated compounds that
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revealed the best activities gave rise spirodioxyselenuranes adducts upon oxidation, while derivatives
with diminished activity generated pincer compounds.
Prevention of oxidative damage and radical scavenging potential were found for the
indol-selenide derivative 51 [88] and the 6-arylselanylpurines 52a and 52b [89], respectively. Apart
from preventing oxidative stress, compound 51 did not show hepatic, renal or cerebral toxicity.
Regarding derivatives 52a and 52b, both presented a significant ABTS radical scavenging activity at
concentrations equal/higher than 100 µM, although only the latter displayed moderated DPPH radical
scavenging activity, at a concentration of 200 µM.
The multifunctional redox naphthalene-1,4-dione selenides (53, 54a, 54b and 55), which combine
more than one redox site in one molecule including a quinone moiety, are particularly suitable to
target (cancer) cells under ROS. Compound 53 seemed to trigger the formation of superoxide in the
mitochondria, since a yeast mutant deficient in superoxide dismutase 2 (SOD2) was hypersusceptible to
it [90]. On the other hand, compound 54b exhibited similar GPx-like activity to ebselen [91], increasing
the initial rate of the reaction by 1.95-fold (ebselen increased the rate by 1.87-fold).
The in vitro antioxidant activities of several chalcogen-based zidovudine
(3′-Azido-3′-deoxythymidine, AZT) analogues have been explored [92]. Firstly, the thiobarbituric acid
reactive substance (TBARS) assay allowed the quantification of the final products of lipid peroxidation
in brain homogenates and showed excellent results for compounds 56b and 56c at two different
concentrations (100 and 200 µM). Additionally, the same compounds were able to decompose H2O2
efficiently and this decomposition involved a 4–5-fold decrease in times required to oxidize 50% of the
benzenethiol in comparison to DMSO (control) and to therapeutically employed AZT.
2.3.2. Antitumoral Activity of Synthetic Selenides
To gain an initial overview of possible cytotoxicity of the naphthalene-1,4-dione derivatives
(53, 54a, 54b and 55, Figure 6), an activity screening was performed in human myeloid leukemia K562
cells [91]. Compound 55 was found to be particularly active at 10 µM, with an average remaining
cell viability of just 8.6%. However, the effect of the latter might also be related to the protected
aldehyde (acetal) function: the reactive aldehyde could be liberated in cells and exert its own toxic
effects. When tested in chronic lymphocytic leukemia (CLL) B-cells isolated from the peripheral blood
(PB) of leukemia patients, compounds 54a and 54b showed strong activity in reducing CLL B-cell
viability at low to submicromolar concentrations [91]. At the same concentrations, viability of healthy
donor peripheral blood mononuclear cells (PBMC) was unaffected by 54a whereas a high toxicity to
healthy control cells was observed for compound 54b. Thus, compound 54a was the most effective
in selectively reducing the viability of CLL cells. This effect was particularly pronounced at 500 nM
and 1 µM. Fludarabine, the major single chemotherapeutic component used in CLL at the moment,
only afforded around 30% reduction of CLL B-cell survival in vitro when used at clinically feasible
doses. The significant reduction of cell survival achieved by 54a at concentrations as low as 500 nM
means that it compares well with such established cytostatics, at least in vitro.
In relation to the above mentioned quinone-containing selenides, the antiproliferative activity
of the 1,2-naphthoquinone-containing selenide (57, Figure 7) was found to be superior to the activity
of other 1,2- and 1,4-naphthoquinone-based chalcogen derivatives [93]. While the IC50 values of the
latter were between 10 and 100 µM and for other 1,2-naphthoquinone derivatives were between 1 and
10 µM, compound 57 was active even in sub-micromolar concentrations against human promyelocytic
leukemia cells (HL-60) and human colon carcinoma cells (HCT-116). The remarkable activity of 57 was
attributed to three factors: the 1,2-naphthoquinone moiety, the Se atom and the electron-withdrawing
substituent in para-position to Se. Unfortunately, no selective cytotoxicity against cancer versus normal
cells was detected.
One of the major limitations in the clinical use of AZT is associated with hepatotoxicity. In fact,
AZT caused a significant reduction in hepatic cell viability at concentrations of 200, 100 and 50 µM
compared with the above-mentioned compound 56c (Figure 6) at 200 µM [92]. When the cytotoxicity
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against bladder carcinoma cells (5637) was tested, AZT proved to be more effective than its derivatives
in inhibiting tumor growth at the lowest concentrations. Nevertheless, at the highest concentrations,
56a–c were more effective and did not cause cellular injury. Derivatives 56a–c also showed better
pro-apoptotic properties than AZT in 5637 cells according to annexin V-binding assays. Thus,
at 50 µM, 56c induced around 70% of apoptosis whereas AZT caused around 8% of apoptosis.
Additionally, the percentage of apoptosis reached 90% by exposure of 5637 cells to 56a–c at 100 µM.
The analysis of DNA fragmentation revealed that 56a–c significantly increased apoptosis-associated
DNA fragmentation comparing to AZT. When the gene expression of anti-apoptotic Bcl-2 and
pro-apoptotic BAX was investigated, the authors found that the BAX: Bcl-2 ratio was affected by
these compounds. Whereas Bcl-2 mRNA levels were significantly lower (compared to control) in cells
exposed to both AZT and 56a–c, BAX mRNA levels were significantly higher except for cells exposed
to AZT. Moreover, a predominance of BAX to Bcl-2 levels, as well as significant increases in caspase-9
mRNA levels, were observed for compounds 56a and 56b in comparison with the controls.Molecules 2018, 22, x  12 of 19 
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Very recently, Zhang et al. [95] studied the antiproliferative activity of several synthetic
indole-chalcone derivatives 59 and the phenylindolyl ketone derivatives 60 and 61 (Figure 7). Most
of these compounds exhibited good to excellent activity (with IC50 values in the sub-micromolar
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level) in six human cancer cell lines: non-small-cell-lung cancer cells (A549), human breast cancer
cells (MDAMB-231), human liver carcinoma cells (HepG2), human epithelial cervical cancer cells
(HeLa), human colon carcinoma cells (HCT-116 and RKO). Among the indole-chalcone derivatives,
the non-substituted indole-3-carbaldehyde 59 exhibited the highest activity (23 to 79 nM). The authors
found that an N-methyl group in the indole moiety was unfavorable and that the activity was related
to the position of substitution on the indole rings. Compound 61 (Figure 7), a phenylindolyl ketone
derivative, exhibited the most potent antiproliferative activities against the six human cancer cell
lines with IC50 values between 4 nM for the A549 cell line and 22 nM for RKO cells. A microtubule
dynamics assay and an immunofluorescence assay confirmed that 61 could effectively inhibit tubulin
polymerization in HeLa cells (IC50 = 2.1 ± 0.27 µM). Further cellular mechanism studies revealed that
61 induced G2/M phase arrest and that apoptosis was associated with a decrease in the mitochondrial
membrane potential ∆ψm. Compared to the reference compound showing an oxygen atom instead
a Se atom, (1H-indol-4-yl)(3,4,5-trimethoxyphenyl)methanone, a remarkable effect of substitution by
selenium was observed, suggesting that the introduction of selenium was beneficial to the antitumor
activity. The activity of 61 also pointed out that the joint position of benzoyl on the indole ring
was important.
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3. Conclusions
Our overview of current selenium compounds with anticancer nd chemopreventive properties
indicates the predominant role for the diaryldiselenide family that is also wider investigated than both
selenides and dialkyldiselenides.
An analysis of the comprehensive studies on (di)selenide compounds shows some
structure–activity rel tionship that can be useful for further search of new selenium anticancer agents
with therapeutic perspective. Thus, the most potent anticancer properti s, with the widest spectrum of
protein targets and mechanisms involved in their action, can be observed for symmetric diselenides
with direct aromatic moieties. The alkyl spacer between an aryl ring and Se usually causes a decrease
of the desirable biological actions.
The role of the aromatic ring properties, including their size, presence of heteroatoms as
well as the number and kind of substituents, is crucial for potency and decisive for mechanisms
of anticancer/chemopreventive action. Various lines of evidence underline an importance of
nitrogen atom, occurred either as exo-amine substituents or as endocyclic heteroatoms of pyridine,
pyridazine, quinolines, indol or purines. More or less electron-withdrawing substituents, i.e., halogens,
trifluoromethyl or nitro groups, at the diphenyl diselenides aromatic rings, play also an important
role and can be found within the structures of apoptosis agents of particularly dangerous human
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cancer lines. However, unsubstituted aromatic rings of diphenyl diselenides have been confirmed as
beneficial for various mechanisms of anticancer and chemopreventive activities, including protection
of murine J774 macrophage-like cells from ROS, an action involving down-regulation of NF-κB or
anti-genotoxic one.
On the other hand, some studies confirm a favorable effect of the electro-donating
methoxy-substituent that causes the chemoprevention increase. The extensive results of anti-cancer
properties of a significant number of selenocompounds show that their symmetric topology is of
particular importance. This is observed not only for diaryl, but also for dialkyl diselenides and for the
less extended family of the selenide agents. Among selenides, the most potent anticancer properties
were identified for the symmetric diallylselenide, although the cyclic compounds are confirmed as
more potent than linear ones. The recent search for anticancer agents has also provided some data
for niche groups of selenium compounds, i.e., the active ferrocene- and peri-diselenides and the less
active selenosteroids.
Considering both the potent anticancer/chemopreventive activity and various mechanisms
of the biological action, selenides and, especially, diselenides described to date, create a library of
“small molecule catalysts” that can be useful for further stages of the antitumor drug research and
development process to give a high probability of finding new therapies against cancer.
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NNK 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
GSH Reduced glutathione
GPx-like Glutathione peroxidase-like
ROS Reactive oxygen species
LDL Low density lipoproteins
NF-κB Nuclear factor-κB DNA Binding
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
Trx Thioredoxin
TrxR Thioredoxin reductase
PDI Disulfide isomerase
2-NP 2-Nitropropane
MT Metallothionein
CDKs Cyclin kinases
IGF-1R Insulin-like growth factor 1 receptor
HDAC Histone deacetylase
SAHA Suberoylanilide hydroxamic acid
DPPH 1,1-Diphenyl-2-picryl-hydrazyl
ABTS 2,2-Azinobis(3-ethylbenzothiazoline- 6-sulfonic acid)
DMBA 7, 12-dimethylbenz(a)anthracene
HPLC High-performance liquid chromatography
NMR Nuclear magnetic resonance
PEG Polyethylene glycol
SOD2 superoxide dismutase 2
PB peripheral blood
PBMC peripheral blood mononuclear cells
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31. Gajdács, M.; Spengler, G.; Sanmartín, C.; Marć, M.A.; Handzlik, J.; Domínguez-Álvarez, E. Selenoesters and
selenoanhydrides as novel multidrug resistance reversing agents: A confirmation study in a colon cancer
MDR cell line. Bioorg. Med. Chem. Lett. 2017, 27, 797–802. [CrossRef] [PubMed]
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